SCHEMBL25815906

SCHEMBL25815906

O=C1CC(C(=O)O)c2c(Br)cccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
SLC22A12 Q96S37 2/20 0.37
ALDH1A1 P00352 1/20 0.37
SLC2A9 Q9NRM0 1/20 0.37
EDNRB P24530 3/20 0.36
EDNRA P25101 3/20 0.36
KDM4E B2RXH2 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
AR P10275 1/20 0.36
CYP19A1 P11511 1/20 0.36
MAOB P27338 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PIM1 P11309 1/20 0.34
CSNK1A1 P48729 1/20 0.34
CDK5 Q00535 1/20 0.34
ROCK1 Q13464 1/20 0.34
DYRK1A Q13627 1/20 0.34
LRRK2 Q5S007 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30356308 1.00 KIF11 (0.39) KIF11SMN1; SMN2SLC22A12ALDH1A1SLC2A9
SCHEMBL25816149 0.81 KIF11 (0.36) KIF11SLC22A12ALDH1A1SLC2A9SIRT2
SCHEMBL30338328 0.81 KIF11 (0.36) KIF11SLC22A12ALDH1A1SLC2A9SIRT2
SCHEMBL7220291 0.80 ACHE (0.40) KIF11SMN1; SMN2ALDH1A1EDNRBEDNRA
SCHEMBL28908862 0.78 ALDH1A1 (0.46) ALDH1A1KDM4EMAOBHSD17B10
SCHEMBL13938126 0.76 ACHE (0.45) ALDH1A1EDNRBEDNRAKDM4EHSD17B10
SCHEMBL2480306 0.75 ACHE (0.41) KIF11PIM1CSNK1A1CDK5ROCK1
SCHEMBL28850201 0.72 ALDH1A1 (0.53) SMN1; SMN2ALDH1A1EDNRBEDNRAKDM4E
SCHEMBL916737 0.72 ALDH1A1 (0.53) SMN1; SMN2ALDH1A1EDNRBEDNRAKDM4E
SCHEMBL7155154 0.71 CYP19A1 (0.48) ALDH1A1KDM4ECYP19A1HSD17B10LDHA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12448363-B2 Kinase inhibitors VIDYA THERAPEUTICS, INC. (US) 2025-10-21 US disclosed
US-20230219923-A1 KINASE INHIBITORS VIDYA THERAPEUTICS, INC. 2023-07-13 US disclosed
US-20230219923-A1 KINASE INHIBITORS VIDYA THERAPEUTICS, INC. 2023-07-13 US disclosed
US-20230219923-A1 KINASE INHIBITORS VIDYA THERAPEUTICS, INC. 2023-07-13 US disclosed
EP-4157446-A1 KINASE INHIBITORS GB002, Inc. (US) 2023-04-05 EP disclosed
CN-115867346-A Kinase inhibitors GB005股份有限公司 2023-03-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12448363-B2 Kinase inhibitors BTK, ABL1, LYN KIF11 3743/4885SMN1; SMN2 4070/4885SLC22A12 4839/4885
US-20230219923-A1 KINASE INHIBITORS BTK, ABL1, LYN KIF11 3743/4885SMN1; SMN2 4070/4885SLC22A12 4839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.